BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29588532)

  • 1. Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance.
    Niskakoski A; Pasanen A; Lassus H; Renkonen-Sinisalo L; Kaur S; Mecklin JP; Bützow R; Peltomäki P
    Mod Pathol; 2018 Aug; 31(8):1291-1301. PubMed ID: 29588532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Niskakoski A; Pasanen A; Porkka N; Eldfors S; Lassus H; Renkonen-Sinisalo L; Kaur S; Mecklin JP; Bützow R; Peltomäki P
    Gynecol Oncol; 2018 Jul; 150(1):92-98. PubMed ID: 29716739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia.
    Nieminen TT; Gylling A; Abdel-Rahman WM; Nuorva K; Aarnio M; Renkonen-Sinisalo L; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Clin Cancer Res; 2009 Sep; 15(18):5772-83. PubMed ID: 19723644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
    Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
    Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG
    JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome.
    Bartosch C; Pires-Luís AS; Meireles C; Baptista M; Gouveia A; Pinto C; Shannon KM; Jerónimo C; Teixeira MR; Lopes JM; Oliva E
    Am J Surg Pathol; 2016 Sep; 40(9):1177-91. PubMed ID: 27340747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
    Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
    Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
    Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.
    Wong S; Hui P; Buza N
    Mod Pathol; 2020 Jun; 33(6):1172-1181. PubMed ID: 31932681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
    Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
    Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
    Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.
    Lim N; Hickey M; Young GP; Macrae FA; Kelly C
    Int J Gynecol Cancer; 2022 May; 32(5):646-655. PubMed ID: 35437274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.